Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 6773-6788

  Amreddy, Narsireddy ^a,b   Muralidharan, Ranganayaki ^a,b   Babu, Anish ^a,b   Mehta, Meghna ^a,b   Johnson, Elyse V ^c   Zhao, Yan D ^b   Munshi, Anupama ^a,b   Ramesh, Rajagopal ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c Cytoviva Inc   (United States)

Author keywords

Doxorubicin; Gold; Lung cancer; Nanoparticles; Transferrin; Tumor targeting

Indexed keywords

DEFEROXAMINE; DOXORUBICIN; GOLD NANOROD; TRANSFERRIN; TRANSFERRIN RECEPTOR; CASPASE 9; GOLD; NANOTUBE;

A549 CELL LINE; APOPTOSIS; ARTICLE; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; CORONARY ARTERY MUSCLE; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG UPTAKE; ENDOCYTOSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; MOLECULARLY TARGETED THERAPY; NANOPHARMACEUTICS; NON SMALL CELL LUNG CANCER; PHYSICAL CHEMISTRY; PROTEIN TARGETING; WESTERN BLOTTING; CELL DEATH; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RELEASE; ENZYME ACTIVATION; KINETICS; LUNG NEOPLASMS; METABOLISM; PH; PROCEDURES; TUMOR CELL LINE; ULTRASTRUCTURE;

CASPASE 9; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; ENDOCYTOSIS; ENZYME ACTIVATION; GOLD; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; LUNG NEOPLASMS; NANOTUBES; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 84946041106     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S93237     Document Type: Article

References (42)

1. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008;77(3):311–319.
2. Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7(2):189–195.
3. Muller I, Jenner A, Bruchelt G, Niethammer D, Halliwell B. Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem Biophys Res Commun. 1997;230(2):254–257.
4. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985;55(12):2761–2765.
5. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377–380.
6. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59(8):748–758.
7. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65(1):3–13.
8. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65(12):5317–5324.
9. Calzolari A, Oliviero I, Deaglio S, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cell Mol Dis. 2007;39(1):82–91.
10. Kawabata H, Yang R, Hirama T, et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem. 1999;274(30):20826–20832.
11. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 2002;54(4):561–587.
12. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121(2):159–176.
13. Dixit S, Novak T, Miller K, Zhu Y, Kenney ME, Broome AM. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale. 2015;7(5):1782–1790.
14. Li JL, Wang L, Liu XY, et al. In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles. Cancer Lett. 2009;274(2):319–326.
15. Wang F, Wang YC, Dou S, Xiong MH, Sun TM, Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano. 2011;5(5):3679–3692.
16. Wijaya A, Schaffer SB, Pallares IG, Hamad-Schifferli K. Selective release of multiple DNA oligonucleotides from gold nanorods. ACS Nano. 2009;3(1):80–86.
17. Salem AK, Searson PC, Leong KW. Multifunctional nanorods for gene delivery. Nat Mater. 2003;2(10):668–671.
18. Huang HC, Barua S, Kay DB, Rege K. Simultaneous enhancement of photothermal stability and gene delivery efficacy of gold nanorods using polyelectrolytes. ACS Nano. 2009;3(10):2941–2952.
19. Chanda N, Shukla R, Katti KV, Kannan R. Gastrin releasing protein receptor specific gold nanorods: breast and prostate tumor avid nanovectors for molecular imaging. Nano Lett. 2009;9(5):1798–1805.
20. Huschka R, Zuloaga J, Knight MW, Brown LV, Nordlander P, Halas NJ. Light-induced release of DNA from gold nanoparticles: nanoshells and nanorods. J Am Chem Soc. 2011;133(31):12247–12255.
21. Sun Z, Ni W, Yang Z, Kou X, Li L, Wang J. pH-controlled reversible assembly and disassembly of gold nanorods. Small. 2008;4(9):1287–1292.
22. Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM, Chada S. Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther. 2004;9(4):510–518.
23. Inoue S, Hartman A, Branch CD, et al. mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007;15(2):287–294.
24. Panneerselvam J, Shanker M, Jin J, et al. Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity. Oncotarget. 2015;6(18):16271–16286.
25. Panneerselvam J, Jin J, Shanker M, et al. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 Signaling Axis. PLoS One. 2015;10(3):e0122439.
26. Kuroda S, Tam J, Roth JA, Sokolov K, Ramesh R. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine. 2014;9:3825–3839.
27. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res. 2008;14(4):1266–1273.
28. Cugia F, Monduzzi M, Ninhamb BW, Salis A. Interplay of ion specificity, pH and buffers: insights from electrophoretic mobility and pH measurements of lysozyme solutions. RSC Adv. 2013;3(17):5882–5888.
29. El-Kareh AW, Secomb TW. Two-mechanism peak concentration model for cellular pharmacodynamics of doxorubicin. Neoplasia. 2005;7(7):705–713.
30. Schafer K, Braun HA, Isenberg C. Effect of menthol on cold receptor activity. Analysis of receptor processes. J Gen Physiol. 1986;88(6):757–776.
31. Moore A, Josephson L, Bhorade RM, Basilion JP, Weissleder R. Human transferrin receptor gene as a marker gene for MR imaging. Radiology. 2001;221(1):244–250.
32. Lebro JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell. 1998;93(1):111–123.
33. Mattia E, Rao K, Shapiro DS, Sussman HH, Klausner RD. Biosynthetic regulation of the human transferrin receptor by desferrioxamine in K562 cells. J Biol Chem. 1984;259(5):2689–2692.
34. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691–1701.
35. Maejima Y, Adachi S, Ito H, Hirao K, Isobe M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell. 2008;7(2):125–136.
36. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of Caspase-9 and Caspase-3 in Leukaemia HL-60 Cells. Eur J Cancer. 1999;35(10):1517–1525.
37. Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY). 2011;3(8):782–793.
38. Sedelnikova OA, William MB. GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle. 2006;5(24):2909–2913.
39. Olive PL, Banáth JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc. 2006;1(1):23–29.
40. Duan X, Xiao J, Yin Q, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013;7(7):5858–5869.
41. Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998;83(5):516–522.
42. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res. 1999;84(3):257–265.